Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Alto Neuroscience, Inc.(ANRO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ANRO
10/23/2026: ANRO (2-star) is currently NOT-A-BUY. Pass it for now.
Alto Neuroscience is a clinical-stage biotechnology company that differentiates itself by using an AI-driven, biomarker-based platform to develop targeted treatments for neuropsychiatric disorders like depression and PTSD. The company's core strength lies in its specialized approach to patient stratification, which aims to improve the success rate of clinical trials in a notoriously difficult therapeutic area. Its growth depends on the successful progression of candidates like ALTO-100 and ALTO-300 through regulatory hurdles. Primary risks include the high likelihood of trial failures, significant capital needs, and intense competition from established pharmaceutical players. The stock is a high-risk, high-reward play best suited for growth-oriented investors focused on clinical milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit while signal remains positive | The company offers high-risk, high-reward exposure to the emerging field of precision psychiatry. |
| Momentum investor | Mixed fit | Momentum depends on clinical trial data readouts, which can lead to significant, binary price swings. |
| Value investor | Weak fit | The company lacks current earnings or traditional valuation metrics, making it unsuitable for traditional value strategies. |
| Dividend investor | Weak fit | Alto Neuroscience does not pay dividends and reinvests all capital into clinical research. |
| Low-risk investor | Weak fit | The speculative nature of biotechnology and binary clinical trial outcomes create high volatility and significant risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks are prone to sharp price changes based on data announcements. |
| Valuation risk | High | Valuations are highly speculative and based on future potential rather than current profits. |
| Competition risk (Biopharmaceutical giants) | Medium / high | Large incumbents have massive R&D budgets that can challenge or outpace smaller specialized players. |
| Business quality | Medium | While the platform is innovative, the company is unproven as a commercial enterprise. |
| Dividend income | Low / none | There is no income generation for shareholders. |
| Execution risk | High | Success depends entirely on the ability to successfully navigate complex, multi-year clinical trials. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 5.81% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 862.15M USD | Price to earnings Ratio - | 1Y Target Price 38.67 |
Price to earnings Ratio - | 1Y Target Price 38.67 | ||
Volume (30-day avg) 672.0K shares | Beta 1.34 | 52 Weeks Range 10.20 - 37.48 | Updated Date 10/24/2026 |
52 Weeks Range 10.20 - 37.48 | Updated Date 10/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.29 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Research and development of proprietary neuropsychiatric drugs. | The company currently makes no money; it burns cash to research drugs in hopes of future regulatory approval. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 956.82M | Price to Sales(TTM) - |
Enterprise Value 956.82M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 39.24M | Shares Floating 29.59M |
Shares Outstanding 39.24M | Shares Floating 29.59M | ||
Percent Insiders 4.21 | Percent Institutions 87.11 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.